Related Experiment Video
Updated: Mar 30, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Clinical Outcomes from Unselected "Real-World" Patients with Long Coronary Lesion Receiving 40 mm Biodegradable
Anurag Polavarapu1, Raghava Sarma Polavarapu1, Jayesh Prajapati2
1Lalitha Super Specialty Hospital Pvt. Ltd., Heart and Brain Centre, Kothapet, Guntur, Andhra Pradesh 522001, India.
Insights
The 40mm Indolimus sirolimus-eluting stent (SES) showed excellent safety and efficacy in real-world patients with long coronary lesions. This biodegradable stent resulted in a low rate of major adverse cardiac events (MACE) at six months.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Long coronary lesions treated with drug-eluting stents (DES) face high restenosis and adverse event rates.
- The 40mm Indolimus sirolimus-eluting stent (SES) utilizes a biodegradable polymer coating.
- Evaluating SES performance in extensive coronary lesions is crucial.
Purpose of the Study:
- To assess the safety and efficacy of the 40mm Indolimus SES in real-world patients with long coronary lesions.
- To determine the incidence of major adverse cardiac events (MACE) and stent thrombosis (ST).
- To evaluate target lesion revascularization (TLR) and target vessel revascularization (TVR) rates.
Main Methods:
- Observational, non-randomized, retrospective, real-world study design.
- Enrolled 258 patients undergoing treatment for long coronary lesions.
- Utilized 40mm Indolimus SES, with primary endpoints assessed at 6-month follow-up.
Main Results:
- A total of 278 lesions were treated with 280 stents.
- The 6-month MACE rate was low at 2.0% (0.8% cardiac death, 1.2% myocardial infarction).
- No instances of TLR, TVR, or ST were observed within the 6-month follow-up period.
Conclusions:
- The 40mm Indolimus SES demonstrated a low MACE rate in real-world patients.
- The stent proved to be a safe and effective treatment option for long coronary lesions.
- Biodegradable polymer sirolimus-eluting stents show promise for complex lesion management.
Abstract:
Background. Long lesions being implanted with drug-eluting stents (DES) are associated with relatively high restenosis rates and higher incidences of adverse events. Objectives. We aimed to examine the safety and efficacy of the long (40 mm) biodegradable polymer coated Indolimus sirolimus-eluting stent (SES) in real-world patients with long coronary lesions. Methods. This study was observational, nonrandomized, retrospective, and carried out in real-world patients. A total of 258 patients were enrolled for the treatment of long coronary lesions, with 40 mm Indolimus. The primary endpoints in the study were incidence of major adverse cardiac events (MACE), a miscellany of cardiac death, myocardial infarction (MI), target lesion revascularization (TLR) or target vessel revascularization (TVR), and stent thrombosis (ST) up to 6-month follow-up. Results. The study population included higher proportion of males (74.4%) and average age was 53.2 ± 11.0 years. A total of 278 lesions were intervened successfully with 280 stents. The observed MACE at 6-month follow-up was 2.0%, which included 0.8% cardiac death and 1.2% MI. There were no TLR or TVR and ST observed during 6-month follow-up. Conclusions. The long (40 mm) Indolimus stent demonstrated low MACE rate and was proven to be safe and effective treatment for long lesions in "real-world" patients.
